Novartis AG Dividend History (NVS)

🤑 Novartis AG has distributed a total of 21 dividends from 2004 to 2024
📈 During this 20 period their dividend has seen a 378.71% increase in the payout amount

About

About Novartis AG

Novartis AG is a leading global healthcare company based in Basel, Switzerland, renowned for its innovative approach in the pharmaceutical industry. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has built a strong reputation for its commitment to research and development, focusing on cutting-edge treatments across various medical fields, including oncology, neuroscience, and immunology. The company is led by CEO Vas Narasimhan, who has been at the helm since 2018, steering Novartis towards a technology-driven future. Under his leadership, Novartis continues to prioritize sustainable practices and patient-centric healthcare solutions. As of 2022, Novartis reported impressive revenues in the vicinity of $51 billion, showcasing its significant impact within the global pharmaceutical market. With a robust pipeline of new drugs and therapies, Novartis remains dedicated to improving patient outcomes worldwide, playing a crucial role in advancing global health standards.

Website: https://www.novartis.com

Other companies you might be interested in

Apple Inc.

Microsoft Corporation

Exxon Mobil Corporation

Verizon Communications Inc.

AT&T Inc.

Chevron Corporation

Company News

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

Novartis announced positive results from a Phase IIIB study evaluating the efficacy and safety of its oral drug Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria who were switched from anti-C5 therapies. The study showed that Fabhalta improved the average hemoglobin level in these patients.

GlobeNewswire Inc. · Published on Fri Dec 06 2024

Global RNA-Targeted Small Molecules Market to Hit USD 4,311.7 Million by 2034, Driven by Advancements in Precision Medicine | Future Market Insights, Inc.

The global RNA-targeted small molecules market is projected to grow from USD 2,453.5 million in 2024 to USD 4,311.7 million by 2034, driven by increasing investments in R&D and the transformative potential of these therapies in addressing genetic and chronic diseases.

GlobeNewswire Inc. · Published on Thu Dec 05 2024

Other companies featured in this article: AZN PFE BMY

Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report

The global coccidioidomycosis drugs market is expected to grow at a CAGR of 4.9% and reach a valuation of US$ 634.3 million by 2034, driven by increased awareness, development in antifungals, and improved access to healthcare in endemic regions.

GlobeNewswire Inc. · Published on Wed Dec 04 2024

Other companies featured in this article: PFE VTRS GILD MRK RDY

Previous Payouts (21)

The most recent dividend Novartis AG paid out was on April 19, 2024 (234 days ago) for $3.7395445 per share

Pay Date	Amount
April 19, 2024	$3.7395445
March 20, 2023	$3.4986993
March 17, 2022	$3.3252497
March 15, 2021	$3.1990725
March 12, 2020	$3.0873655
March 13, 2019	$2.834128
April 25, 2018	$2.936451
April 20, 2017	$2.717759
April 15, 2016	$2.717946
April 20, 2015	$2.816901
April 10, 2014	$2.759789
April 5, 2013	$2.42647
April 5, 2012	$2.482145
April 8, 2011	$2.36336
April 13, 2010	$1.948359
April 6, 2009	$1.720134
April 11, 2008	$1.537471
April 10, 2007	$1.096517
April 3, 2006	$0.880052
April 6, 2005	$0.88322
March 30, 2004	$0.78117

Dividend data last updated Sun, 08 Dec 2024 13:33:53 GMT UTC